Normalizing the exceptional: Incorporating the "abortion pill" into mainstream medicine

Social Science and Medicine

Volumn 56, Issue 12, 2003, Pages 2353-2366

  Joffe, Carole ^a   Weitz, Tracy A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Abortion; Mifepristone; Technological diffusion; United States

Indexed keywords

ABORTIVE AGENT; MIFEPRISTONE; MISOPROSTOL;

ABORTION;

ABORTION; BACTERIAL INFECTION; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CULTURAL FACTOR; DRUG APPROVAL; DRUG COST; DRUG DIFFUSION; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; ECHOGRAPHY; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE SYSTEM; HEART INFARCTION; HUMAN; LEGAL ASPECT; MALPRACTICE; MEDICAL SPECIALIST; PATIENT COMPLIANCE; PHYSICIAN; REIMBURSEMENT; REVIEW; SOCIAL ASPECT;

EID: 0013109966     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0277-9536(02)00240-X     Document Type: Article

References (87)

1. ACOG. (2000). ACOG writes FDA on safety of misoprostol (News Release). Washington DC: American College of Obstetricians and Gynecologists.
2. AGI. (2000). Facts in brief: Induced abortion (February), (www). The Alan Guttmacher Institute (AGI). Available at http://www.agi-usa.org/pubs/fb_induced_abortion.html [September 20, 2001].
3. Almeling R., Tews L., Dudley S. Abortion training in US obstetrics and gynecology residency programs, 1998. Family Planning Perspectives. 32(6):2000;268.
4. American Association of Pro Life Obstetricians and Gynecologists. (2001, 8/21/01). American Association of Pro Life Obstetricians and Gynecologists (www). American Association of Pro Life Obstetricians and Gynecologists [September 21, 2001].
5. Ashok P.W., Penney G.C., Flett G.M., Templeton A. An effective regimen for early medical abortion. A report of 2000 consecutive cases Human Reproduction. 13(10):1998;2962-2682965.
6. Atkinson P. Medical talk and medical work. The liturgy of the clinic:1995;Sage, London.
7. Banta, H. D., & Luce, B. R. (1993). Health care technology and its assessment: An international perspective. Oxford, UK; New York, NY: Oxford University Press.
8. Beckman L.J., Harvey S.M. The new civil war. The psychology, culture, and politics of abortion:1998;American Psychological Association, Washington, DC.
9. Berkowitz B.A., Katzung B.G. Basic and clinical evaluation of new drugs. Katzung B.G. Basic and clinical pharmacology. 8th ed. 2001;64-74 Lange Medical Books/McGraw-Hill, New York.
10. Boonstra, H. (2001). Voicing concern for women, abortion foes seek limits on availability of mifepristone. The Guttmacher Report on Public Policy, (pp. 3-7).
11. Borgmann C.E., Jones B.S. Legal issues in the provision of medical abortion. American Journal of Obstetrics and Gynecology. 183(Suppl 2):2000;S84-S94.
12. Center for Reproductive Law and Policy. (1998). Roe v. Wade and "Partial Birth Abortion" Bans, (www). Center for Reproductive Law and Policy. Available at http://www.crlp.org/pub_fac_roepb.html [November 14, 2001).
13. Clarke A., Montini T. The many faces of RU486. Tales of situated knowledges and technological contestations Science, Technology, & Human Values. 18(1):1993;42-79.
14. Clinicians for Choice. (1996). The role of physician assistants, nurse practitioners, and nurse-midwives in providing abortions: Strategies for Expanding Abortion Access.
15. Coalition on Abortion/Breast Cancer. (2001). What is RU 486 and how does it work? (www). Coalition on abortion/breast cancer. Available at http://abortionbreastcancer.com/whatisru486.htm [September 20, 2001].
16. Council on Scientific Affairs American Medical Association. (1992). Induced termination of pregnancy before and after Roe v Wade. Trends in the mortality and morbidity of women. Journal of the American Medical Association, 268(22), 3231-3239.
17. Cullen, M. (2000). Important drug warning concerning unapproved use of intravaginal or oral misoprostol in pregnant women for induction of labor or abortion (letter). Skokie, IL: G.D. Searle & Co.
18. Danco Laboratories. (2000a). Mifeprex™ (mifepristone) tablets, 200 mg, prescriber's agreement, (www). Danco Laboratories. Available at http://www.earlyoptionpill.com/prescribers_agreement.pdf [September 2001].
19. Danco Laboratories. (2000b). Using mifeprex™: medication guide (www). Danco Laboratories. Available at http://www.earlyoptionpill.com/may_guide.php3 [September, 2001].
20. DiMasi J.A., Hansen R.W., Grabowski H.G., Lasagna L. Cost of innovation in the pharmaceutical industry. Journal of Health Economics. 10(2):1991;107-142.
21. Duin, J. (2001). Ad for abortion pill challenged. The Washington Times, (p. 3).
22. Ellertson C., Elul B., Ambardekar S., Wood L., Carroll J., Coyaji K. Accuracy of assessment of pregnancy duration by women seeking early abortions. Lancet. 355(9207):2000;877-881.
23. Elul B., Pearlman E., Sorhaindo A., Simonds W., Westhoff C. In-depth interviews with medical abortion clients. Thoughts on the method and home administration of misoprostol Journal of the American Medical Women's Association. 55(3Suppl):2000), 169-172.
24. Epstein S. Impure science. Aids, activism, and the politics of knowledge:1996;University of California Press, Berkeley.
25. Feminist Majority. (2001). Feminist Majority Foundation's Mifepristone Compassionate Use Program (www). Feminist majority. Available at http://www.feminist.org/rrights/compassionateuse.asp#5 [September 20, 2001].
26. Food and Drug Administration. (1982). Use of approved drugs for unlabeled indications, Vol. 12 (pp. 4-5). Washington, DC: FDA Bulletin.
27. Freidson E. Profession of medicine. A study of the sociology of applied knowledge:1970;Dodd Mead, New York.
28. Freidson E. Professional dominance. The social structure of medical care:1970;Atherton Press, New York.
29. Grimes D.A. Clinicians who provide abortions. The thinning ranks Obstetrics and Gynecology. 80(4):1992;719-723.
30. Hakim-Elahi E., Tovell H.M., Burnhill M.S. Complications of first-trimester abortion. A report of 170,000 cases Obstetrics and Gynecology. 76(1):1990;129-135.
31. Henshaw, S. K. (1998). Abortion incidence and services in the United States, 1995-1996. Family Planning Perspectives, 30(6), 263-270, 287.
32. Hilts, P. J. (1996). Giving push to the abortion pill, a second US group will test it. New York Times, (p. A9).
33. Hodgson J.E. The twentieth-century gender battle. Difficulties in perception Solinger R. Abortion wars: A half century of struggle, 1950-2000. 1998;290-306 University of California Press, Berkeley.
34. Hoffman L.M. The politics of knowledge. Activist movements in medicine and planning:1989;State University of New York Press, Albany, NY.
35. Jasper, W. F. (2000, November 6). Unleashing the Killer Pill. The New American, (p. 16).
36. Joffe C.E. Doctors of conscience. The struggle to provide abortion before and after Roe v. Wade:1995;Beacon Press, Boston.
37. Joffe C. Reactions to medical abortion among providers of surgical abortion. An early snapshot Family Planning Perspectives. 31(1):1999;35.
38. Joffe C. Medical abortion and the potential for new abortion providers. A cautionary tale Journal of the American Medical Women's Association. 55(3 Suppl):2000;151-35154.
39. Joffe, C., Anderson, P., & Steinauer, J. (1998). The crisis in abortion provision and pro-choice medical activism in the 1990s. In: R. Solinger (Ed.), Abortion wars: A half century of struggle, 1950-2000 (pp. 320-333). Berkeley: University of California Press.
40. Kaiser Family Foundation. (1997). National Survey of Ob/Gyns about Abortion. Menlo Park, CA: The Henry J. Kaiser Family Foundation.
41. Kaufman, M. (2000). FDA again delays abortion pill approval; Questions on the manufacturing and labeling of RU-486 remain unresolved. Washington Post, (p. A02).
42. Kohn L.T., Corrigan J.M., Donaldson M.S. Executive summary. Kohn L.T., Corrigan J.M., Donaldson M.S. To err is human: Building a health system. 2000;1-16 National Academy Press, Washington, DC.
43. Kolata, G. (2000). Doctors looking at abortion pill are often unaware of obstacles; many state laws already regulate drug's use. New York Times, (p. A1).
44. Lader L. A private matter. RU 486 and the abortion crisis:1995;Prometheus Books, Amherst, NY.
45. Landy U., Steinauer J.E. How available is abortion training? Family Planning Perspectives. V33(N2):2001;88-89.
46. Latour B. The pasteurization of France. 1988;Harvard University Press, Cambridge MA.
47. Lichstein P.R., Turner R.C., O'Brien K. Impact of pharmaceutical company representatives on internal medicine residency programs. A survey of residency program directors. Archives of Internal Medicine. 152(5):1992;1009-1013.
48. Lo C. Countermovements and conservative movements in the contemporary US. Annual Review of Sociology. 8:1982;107-134.
49. Lo M.C. Doctors within borders. Profession, ethnicity, and modernity in colonial Taiwan:2002;University of California Press, Berkeley, CA.
50. Luker K. Abortion and the politics of motherhood. 1984;University of California Press, Berkeley.
51. MacKay H.T., MacKay A.P. Abortion training in obstetrics and gynecology residency programs in the United States, 1991-1992. Family Planning Perspectives. 27(3):1995;112-115.
52. McKinlay J.B., Hafferty F.W. The changing medical profession. An international perspective:1993;Oxford University Press, New York.
53. Michelman, K. (2001). Anti-choice Lawmakers Attack the Right to Choose (www). National abortion. Available at http://www.naral.com/mediaresources/press/2001/pr042601_uvva.html [November 14, 2001].
54. NARAL. (2001). Who decides?: A state-by-state review of abortion and reproductive rights (10th ed.). Washington, DC: The NARAL Foundation/NARAL.
55. National Abortion Federation. (1991). Who will provide abortions? Ensuring the availability of qualified practitioners. Washington, DC: National Abortion Federation.
56. National Abortion Federation. (2001). Early medical abortion with methotrexate and mifepristone: Overview and protocol recommendations. Washington, DC: National Abortion Federation.
57. National Pro-Life/Pro-Family Organizations. (2001). US Prolife Directory (www). Catholic.Net. Available at http://www.catholic.net/RCC/Prolife/prolife2.html [September 20, 2001].
58. National Right to Life Committee. (2001a). Approval and lingering issues of RU-486 (www). National Right to Life Committee. Available at http://nrlc.org/RU-486/RU486lingeringissues.html [May 2001].
59. National Right to Life Committee. (2001b). RU486: The pill, the process, the problems (www). National Right to Life Committee. Available at http://www.nrlc.org/RU486/ru486info.html [November 14, 2001].
60. Novaes H.M. Social impacts of technological diffusion. Prenatal diagnosis and induced abortion in Brazil Social Science & Medicine. 50(1):2000;41-51.
61. Okie, S. (2002). Physicians sent abortion pill alert. Washington Post, 18 (p. A02).
62. Pan, P. P. (2000). Chinese to make RU-486 For US; FDA has sought to shield source of abortion drug. Washington Post (p. A01).
63. Pear, R. (2001). Thompson says he will order a new review of abortion drug. New York Times, (p. A11).
64. Petchesky R.P. Abortion and woman's choice. the state, sexuality, and reproductive freedom:1984;Longman, New York.
65. Pharmacia Corporation. (2001). About pharmacia (www). Pharmacia corporation. Available at http://www.pharmacia.com/about/history.asp [November 14, 2001].
66. Public Citizen. (2001a). Executive summary (www). Public Citizen. Available at http://www.citizen.org/publications/release.cfm?ID=7065 [September 20, 2001].
67. Public Citizen. (2001b). Rx R&D myths: The case against the drug industry's R&D "Scare Card" (Congress Watch). Washington DC: Public Citizen.
68. Reproductive Freedom Task Force. (2000). Speak out against Dr. Steir's sentencing! (www). Refuse and resist! Available at http://www.refuseandresist.org/ab/080101pendergraft.html [November 14, 2001].
69. Reproductive Freedom Task Force. (2001). Abortion provider Dr. James pendergraft now in Atlanta Federal Prison, denied his freedom while his case is being appealed (www). Refuse and resist! Available at http://www.refuseandresist.org/ab/080101pendergraft.html [November 14, 2001].
70. Rubin E.R. The abortion controversy. A documentary history:1994;Greenwood, Westport, CT.
71. Ruzek S.B., Clarke A., Olesen V.L. Women's health. Complexities and differences:1997;Ohio State University Press, Columbus.
72. Schaff E.A., Eisinger S.H., Stadalius L.S., Franks P., Gore B.Z., Poppema S. Low-dose mifepristone 200. mg and vaginal misoprostol for abortion Contraception. 59(1):1999;1-6.
73. Schaff E.A., Fielding S.L. A comparison of the abortion rights mobilization and population council trials. Journal of the American Medical Women's Association. 55(3 Suppl):2000;137-140.
74. Schaff E.A., Fielding S.L., Eisinger S.H., Stadalius L.S., Fuller L. Low-dose mifepristone followed by vaginal misoprostol at 48. h for abortion up to 63 days Contraception. 61(1):2000;41-46.
75. Schaff, E. A., Fielding, S. L., Westhoff, C., Ellertson, C., Eisinger, S. H., Stadalius, L. S., & Fuller, L. (2000b). Vaginal misoprostol administered 1, 2 or 3 days after mifepristone for early medical abortion: A randomized trial. [Erratum In: JAMA November 22-29, 2000, 284(20), p.2597]. Journal of the American Medical Association, 284(15), 1948-1953.
76. Schaff E.A., Stadalius L.S., Eisinger S.H., Franks P. Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. Journal of Family Practice. 44(4):1997;353-360.
77. Schweitzer S.O. Pharmaceutical economics and policy. 1997;Oxford University Press, New York.
78. Seckora, M. (2001). Making America safe for RU-486: The FDA fudged its own rules (www). Pro-life infornet. Available at http://www.euthanasia.com/486approval.html [July 13, 2001].
79. Simonds W., Ellertson C., Winikoff W., Springer K. Providers, pills and power. The US mifepristone abortion trials and caregivers' interpretations of clinical power dynamics Health. 5(2):2001;207-232.
80. Solinger, R. (Ed.). (1998). Abortion wars: A half century of struggle, 1950-2000. Berkeley: University of California Press.
81. Stewart, F. H., Wells, E. S., Flinn, S. K., & Weitz, T. A. (2001). Early medical abortion: Issues for practice. San Francisco, CA: University of California, San Francisco Center for Reproductive Health Research and Policy.
82. Talbot, M. (1999). The little white bombshell. New York Times Magazine, (pp. 38-43, 48, 61-63).
83. Turner B.S., Samson C. Medical power and social knowledge. 2nd Ed. 1995;Thousand Oaks, Sage Publications, London.
84. Ulmann A. The development of mifepristone. A pharmaceutical drama in three acts Journal of the American Medical Womens Association. 55(3 Suppl):2000;117-120.
85. US Food and Drug Administration. (1998). FDA approves thalidomide For Hansen's disease side effect, imposes unprecedented restrictions on distribution (FDA Talk Paper). Rockville, MD: Food and Drug Administration, US Department of Health and Human Services.
86. World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation. (2000). Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: A randomised trial. British Journal of Obstetrics and Gynaecology, 107(4), 524-530.
87. Zimmerman, R., & Lueck, S. (2000). Abortion-rights leaders fight FDA limits on RU-486; meeting will plot strategy - from lobbying to ads - to ensure access. Wall Street Journal, (p. B6).